Amundi
IOVA icon

Amundi’s Iovance Biotherapeutics IOVA Stock Holding History

Amundi’s Portfolio IOVA Stock Details IOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-10,932
Closed -$64.2K – 2077
2023
Q1 		$64.2K Hold
10,932
– – ﹤0.01% 1841
2022
Q4 		$67.1K Sell
10,932
-6,781
-38% -$52.9K ﹤0.01% 1660
2022
Q3 		$175K Buy
17,713
+10,932
+161% +$126K ﹤0.01% 1473
2022
Q2 		$86K Sell
6,781
-1,503
-18% -$19.7K ﹤0.01% 1474
2022
Q1 		$151K Hold
8,284
– – ﹤0.01% 1417
2021
Q4 		$126K Buy
8,284
+684
+9% +$15.1K ﹤0.01% 1541
2021
Q3 		$187K Hold
7,600
– – ﹤0.01% 1448
2021
Q2 		$198K Buy
+7,600
New +$198K ﹤0.01% 1379

Other funds holding IOVA

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
MFM
MHR Fund Management New York $1.92B AUM 119.57% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
PAMS
Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return

Amundi's IOVA Position: Q2 2023 in Review

Amundi sold out of Iovance Biotherapeutics (IOVA) in Q2 2023, closing a stake of 10,932 shares — an estimated $64.2K sold.

Amundi first reported a position in IOVA in Q2 2021 and held it in 8 quarters. The position peaked at $198K in Q2 2021. 219 funds tracked by Wall St. Rank hold IOVA as of Q2 2023.

  • Amundi reported no remaining Iovance Biotherapeutics position as of Q2 2023 after selling out during the quarter.
  • Amundi sold 10,932 Iovance Biotherapeutics shares in Q2 2023, an estimated $64.2K.
  • Amundi first reported a position in Iovance Biotherapeutics in Q2 2021 and held it in 8 quarters.
  • Amundi's Iovance Biotherapeutics position peaked at $198K in Q2 2021.
  • 219 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q2 2023.

Based on Amundi's 13F filing for Q2 2023, filed 14 Aug 2023.